{"id": "article-17403_0", "title": "Alport Syndrome -- Continuing Education Activity", "content": "Alport syndrome is a genetic condition characterized by kidney disease, loss of hearing, and eye abnormalities. It occurs due to an abnormality of a gene that codes for type 4 collagen and usually presents in patients with hematuria, edema, and hypertension. In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by COL4A5 gene mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant pattern by mutations in COL4A3 or COL4A4 gene. This activity illustrates the evaluation and management of Alport syndrome and reviews the role of the interprofessional team in improving care for patients suffering from this condition.", "contents": "Alport Syndrome -- Continuing Education Activity. Alport syndrome is a genetic condition characterized by kidney disease, loss of hearing, and eye abnormalities. It occurs due to an abnormality of a gene that codes for type 4 collagen and usually presents in patients with hematuria, edema, and hypertension. In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by COL4A5 gene mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant pattern by mutations in COL4A3 or COL4A4 gene. This activity illustrates the evaluation and management of Alport syndrome and reviews the role of the interprofessional team in improving care for patients suffering from this condition."}
{"id": "article-17403_1", "title": "Alport Syndrome -- Continuing Education Activity", "content": "Objectives: Identify the etiology of Alport syndrome. Summarize the pathophysiology of Alport syndrome. Describe the use of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin 2 receptor blockers (ARBs) in managing Alport syndrome. Outline the importance of collaboration and communication among the interprofessional team to enhance care coordination for patients affected by Alport syndrome. Access free multiple choice questions on this topic.", "contents": "Alport Syndrome -- Continuing Education Activity. Objectives: Identify the etiology of Alport syndrome. Summarize the pathophysiology of Alport syndrome. Describe the use of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin 2 receptor blockers (ARBs) in managing Alport syndrome. Outline the importance of collaboration and communication among the interprofessional team to enhance care coordination for patients affected by Alport syndrome. Access free multiple choice questions on this topic."}
{"id": "article-17403_2", "title": "Alport Syndrome -- Introduction", "content": "The term Alport syndrome is used to describe a group of heterogeneous inherited disorders involving the basement membrane of the kidney and commonly affecting the cochlea and eye. [1] [2] Alport syndrome, also known as hereditary nephritis, is a genetic disorder\u00a0arising from the mutations in the genes encoding alpha-3, alpha-4, and alpha-5 of\u00a0type 4 collagen (COL4A3, COL4A4, COL4A5) or collagen 4 \u03b1345 network. [3]", "contents": "Alport Syndrome -- Introduction. The term Alport syndrome is used to describe a group of heterogeneous inherited disorders involving the basement membrane of the kidney and commonly affecting the cochlea and eye. [1] [2] Alport syndrome, also known as hereditary nephritis, is a genetic disorder\u00a0arising from the mutations in the genes encoding alpha-3, alpha-4, and alpha-5 of\u00a0type 4 collagen (COL4A3, COL4A4, COL4A5) or collagen 4 \u03b1345 network. [3]"}
{"id": "article-17403_3", "title": "Alport Syndrome -- Introduction", "content": "The type 4 collagen alpha chains are primarily located in the kidneys, eyes, and cochlea. Alport syndrome is X-linked (XLAS) and can be transmitted in an autosomal recessive (ARAS) or autosomal dominant fashion (ADAS).\u00a0In 1927, the syndrome of hereditary nephritis and deafness was described by a British physician, A. Cecil Alport. It was\u00a0observed that hematuria was the most common symptom, and males were affected more than females. In 1961, it was named Alport syndrome after having been\u00a0observed in multiple family members. [4] [5] [6] It is\u00a0characterized\u00a0by renal failure, bilateral sensorineural hearing loss, and eye abnormalities. Eventually, the patients present with proteinuria, hypertension, progressive loss of kidney function (gradual decline in GFR), and end-stage renal disease (ESRD). [7]", "contents": "Alport Syndrome -- Introduction. The type 4 collagen alpha chains are primarily located in the kidneys, eyes, and cochlea. Alport syndrome is X-linked (XLAS) and can be transmitted in an autosomal recessive (ARAS) or autosomal dominant fashion (ADAS).\u00a0In 1927, the syndrome of hereditary nephritis and deafness was described by a British physician, A. Cecil Alport. It was\u00a0observed that hematuria was the most common symptom, and males were affected more than females. In 1961, it was named Alport syndrome after having been\u00a0observed in multiple family members. [4] [5] [6] It is\u00a0characterized\u00a0by renal failure, bilateral sensorineural hearing loss, and eye abnormalities. Eventually, the patients present with proteinuria, hypertension, progressive loss of kidney function (gradual decline in GFR), and end-stage renal disease (ESRD). [7]"}
{"id": "article-17403_4", "title": "Alport Syndrome -- Etiology", "content": "In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by COL4A5 gene\u00a0mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant\u00a0pattern by mutations in COL4A3 or COL4A4 gene. Approximately 80% of men with XLAS\u00a0develop some hearing loss until they reach their teenage years. [8]", "contents": "Alport Syndrome -- Etiology. In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by COL4A5 gene\u00a0mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant\u00a0pattern by mutations in COL4A3 or COL4A4 gene. Approximately 80% of men with XLAS\u00a0develop some hearing loss until they reach their teenage years. [8]"}
{"id": "article-17403_5", "title": "Alport Syndrome -- Etiology", "content": "Alport syndrome is caused by mutations in the genes responsible for alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The following three genetic forms of Alport syndrome are mentioned with their proximate causes: XLAS - caused by mutations in the COL4A5 gene; 85% of cases of Alport syndrome [9] ARAS - due to mutations in COL4A3 or COL4A4 gene; leading to approximately 10-15% of cases ADAS - caused by mutations in the COL4A3 or COL4A4 gene, although rare", "contents": "Alport Syndrome -- Etiology. Alport syndrome is caused by mutations in the genes responsible for alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The following three genetic forms of Alport syndrome are mentioned with their proximate causes: XLAS - caused by mutations in the COL4A5 gene; 85% of cases of Alport syndrome [9] ARAS - due to mutations in COL4A3 or COL4A4 gene; leading to approximately 10-15% of cases ADAS - caused by mutations in the COL4A3 or COL4A4 gene, although rare"}
{"id": "article-17403_6", "title": "Alport Syndrome -- Etiology", "content": "Over 300 mutations have been observed in the COL4A5 genes in families with XLAS. Majorly, COL4A5 mutations are minor, including splice-site mutations, missense mutations, and deletions of fewer than ten base pairs.", "contents": "Alport Syndrome -- Etiology. Over 300 mutations have been observed in the COL4A5 genes in families with XLAS. Majorly, COL4A5 mutations are minor, including splice-site mutations, missense mutations, and deletions of fewer than ten base pairs."}
{"id": "article-17403_7", "title": "Alport Syndrome -- Etiology", "content": "Around 20% of the mutations are large and medium-sized deletions in the COL4A5 gene. A certain kind of deletion involving the COL4A5 and COL4A6 genes leads to a combination of XLAS and leiomyomatosis of the esophagus, female genital tract, and tracheobronchial tree. [10]", "contents": "Alport Syndrome -- Etiology. Around 20% of the mutations are large and medium-sized deletions in the COL4A5 gene. A certain kind of deletion involving the COL4A5 and COL4A6 genes leads to a combination of XLAS and leiomyomatosis of the esophagus, female genital tract, and tracheobronchial tree. [10]"}
{"id": "article-17403_8", "title": "Alport Syndrome -- Etiology", "content": "In patients with Alport syndrome, to date, only six mutations in the COL4A3 gene and twelve mutations in the COL4A4 gene are seen in patients with ARAS. The mutations include frameshift deletions, amino acid substitutions, missense mutations, splicing mutations, and in-frame deletions.", "contents": "Alport Syndrome -- Etiology. In patients with Alport syndrome, to date, only six mutations in the COL4A3 gene and twelve mutations in the COL4A4 gene are seen in patients with ARAS. The mutations include frameshift deletions, amino acid substitutions, missense mutations, splicing mutations, and in-frame deletions."}
{"id": "article-17403_9", "title": "Alport Syndrome -- Epidemiology", "content": "Alport syndrome affects about 1 in 50,000 newborns, and males are more likely to be symptomatic than females. It is estimated that approximately 30,000 to 60,000 people in the United States (US) have this disorder. In the US,\u00a0the overall incidence of end-stage renal disease (ESRD) in children is about 3% and 0.2% in the adult population. [11] [12] Alport syndrome accounts for approximately 2.2% of children and 0.2% of adults with ESRD in the United States. In Europe, Alport syndrome accounts for 0.6% of patients with ESRD.", "contents": "Alport Syndrome -- Epidemiology. Alport syndrome affects about 1 in 50,000 newborns, and males are more likely to be symptomatic than females. It is estimated that approximately 30,000 to 60,000 people in the United States (US) have this disorder. In the US,\u00a0the overall incidence of end-stage renal disease (ESRD) in children is about 3% and 0.2% in the adult population. [11] [12] Alport syndrome accounts for approximately 2.2% of children and 0.2% of adults with ESRD in the United States. In Europe, Alport syndrome accounts for 0.6% of patients with ESRD."}
{"id": "article-17403_10", "title": "Alport Syndrome -- Epidemiology", "content": "The common X-linked type of Alport syndrome resulting in ESRD predominantly affects males. However, the X-linked form of Alport syndrome affects almost as many females. Affected women are generally undiagnosed, but 15%\u201330% end up having renal failure by 60 years and hearing loss by middle age. [13]", "contents": "Alport Syndrome -- Epidemiology. The common X-linked type of Alport syndrome resulting in ESRD predominantly affects males. However, the X-linked form of Alport syndrome affects almost as many females. Affected women are generally undiagnosed, but 15%\u201330% end up having renal failure by 60 years and hearing loss by middle age. [13]"}
{"id": "article-17403_11", "title": "Alport Syndrome -- Epidemiology", "content": "Alport syndrome is a significant cause of chronic kidney disease (CKD), leading to ESRD in adolescents and young adults, accounting for 1.5%\u00a0to 3.0% of children on renal replacement therapies in Europe and the US. [14]", "contents": "Alport Syndrome -- Epidemiology. Alport syndrome is a significant cause of chronic kidney disease (CKD), leading to ESRD in adolescents and young adults, accounting for 1.5%\u00a0to 3.0% of children on renal replacement therapies in Europe and the US. [14]"}
{"id": "article-17403_12", "title": "Alport Syndrome -- Pathophysiology", "content": "The pathophysiology of Alport syndrome is impaired production and deposition of collagen 4 \u03b1345 network in the basement membranes of the glomerulus, cochlea (inner ear), and eye. ARAS transmission is due to mutations in both the alleles of COL4A3 and COL4A4, whereas ADAS is caused by heterozygous mutations. With the use of next-generation sequencing (NGS), it has been shown that ADAS accounts for a greater number of cases. Compared to XLAS, patients with ADAS have a slower rate of progression to ESRD and are less likely to have extra-renal manifestations. [15] [16] The glomerular basement membrane (GBM) in Alport syndrome is more prone to proteolytic injury leading to activation of adhesion kinase in podocytes, endothelin receptors, glomerular inflammation, tubulointerstitial fibrosis, and ESRD. [17] [18] [19] [20]", "contents": "Alport Syndrome -- Pathophysiology. The pathophysiology of Alport syndrome is impaired production and deposition of collagen 4 \u03b1345 network in the basement membranes of the glomerulus, cochlea (inner ear), and eye. ARAS transmission is due to mutations in both the alleles of COL4A3 and COL4A4, whereas ADAS is caused by heterozygous mutations. With the use of next-generation sequencing (NGS), it has been shown that ADAS accounts for a greater number of cases. Compared to XLAS, patients with ADAS have a slower rate of progression to ESRD and are less likely to have extra-renal manifestations. [15] [16] The glomerular basement membrane (GBM) in Alport syndrome is more prone to proteolytic injury leading to activation of adhesion kinase in podocytes, endothelin receptors, glomerular inflammation, tubulointerstitial fibrosis, and ESRD. [17] [18] [19] [20]"}
{"id": "article-17403_13", "title": "Alport Syndrome -- Pathophysiology", "content": "The primary pathology in patients with Alport syndrome\u2014causing abnormality in the basement membrane\u2014is present in the noncollagenous (NC1) C-terminal of the alpha-5 chain in XLAS and that of alpha-3 or alpha-4 chains in ARAS and ADAS.", "contents": "Alport Syndrome -- Pathophysiology. The primary pathology in patients with Alport syndrome\u2014causing abnormality in the basement membrane\u2014is present in the noncollagenous (NC1) C-terminal of the alpha-5 chain in XLAS and that of alpha-3 or alpha-4 chains in ARAS and ADAS."}
{"id": "article-17403_14", "title": "Alport Syndrome -- Pathophysiology", "content": "In the early development of the kidney, alpha-1 and alpha-2 chains are predominant in the glomerular basement membrane (GBM). With maturation, alpha-3, alpha-4, and alpha-5 chains become dominant\u00a0through isotype switching. Evidence suggests that alpha-3, alpha-4, and alpha-5 chains combine to produce a unique collagen network. Abnormalities in any of these chains, as seen in patients with Alport syndrome, impair the formation of the collagen network leading to aberrant incorporation of the other collagen chains.", "contents": "Alport Syndrome -- Pathophysiology. In the early development of the kidney, alpha-1 and alpha-2 chains are predominant in the glomerular basement membrane (GBM). With maturation, alpha-3, alpha-4, and alpha-5 chains become dominant\u00a0through isotype switching. Evidence suggests that alpha-3, alpha-4, and alpha-5 chains combine to produce a unique collagen network. Abnormalities in any of these chains, as seen in patients with Alport syndrome, impair the formation of the collagen network leading to aberrant incorporation of the other collagen chains."}
{"id": "article-17403_15", "title": "Alport Syndrome -- Pathophysiology", "content": "Evidence shows that isoform switching of type IV collagen is developmentally arrested in XLAS. [21] This causes the\u00a0perpetuation of the fetal distribution of alpha-1 and alpha-2 isoforms and a complete lack of alpha-3, alpha-4, and alpha-5 isoforms. The anomalous retention of alpha-1 and alpha-2 isoforms makes GBM prone to proteolytic enzymes, causing basement membrane splitting and damage.", "contents": "Alport Syndrome -- Pathophysiology. Evidence shows that isoform switching of type IV collagen is developmentally arrested in XLAS. [21] This causes the\u00a0perpetuation of the fetal distribution of alpha-1 and alpha-2 isoforms and a complete lack of alpha-3, alpha-4, and alpha-5 isoforms. The anomalous retention of alpha-1 and alpha-2 isoforms makes GBM prone to proteolytic enzymes, causing basement membrane splitting and damage."}
{"id": "article-17403_16", "title": "Alport Syndrome -- Pathophysiology", "content": "Patients who develop anti-GBM nephritis have circulating anti-GBM antibodies. In patients with ARAS, antibodies bind to the alpha-3 and alpha-4 collagen chains, whereas in patients with XLAS, antibodies predominantly bind to the alpha-5 chain. [22] [23] [24] Native kidneys do not express the antigens recognized by the anti-GBM antibodies\u00a0but are expressed in the transplanted kidneys, which are recognized by these antibodies.", "contents": "Alport Syndrome -- Pathophysiology. Patients who develop anti-GBM nephritis have circulating anti-GBM antibodies. In patients with ARAS, antibodies bind to the alpha-3 and alpha-4 collagen chains, whereas in patients with XLAS, antibodies predominantly bind to the alpha-5 chain. [22] [23] [24] Native kidneys do not express the antigens recognized by the anti-GBM antibodies\u00a0but are expressed in the transplanted kidneys, which are recognized by these antibodies."}
{"id": "article-17403_17", "title": "Alport Syndrome -- Pathophysiology", "content": "Posttransplant anti-GBM nephritis generally\u00a0appears within the first year of transplant. Patients have rapidly progressive glomerulonephritis with kidney biopsy revealing linear immune deposits along the GBM and crescentic glomerulonephritis. Contrary to de novo anti-GBM nephritis, lung hemorrhage is never seen in posttransplant anti-GBM nephritis in cases of Alport syndrome. Plasmapheresis and cyclophosphamide are generally unsuccessful, and most patients lose the allograft. [25] However, there have been cases of successful treatment with intravenous immunoglobulins and plasmapheresis.", "contents": "Alport Syndrome -- Pathophysiology. Posttransplant anti-GBM nephritis generally\u00a0appears within the first year of transplant. Patients have rapidly progressive glomerulonephritis with kidney biopsy revealing linear immune deposits along the GBM and crescentic glomerulonephritis. Contrary to de novo anti-GBM nephritis, lung hemorrhage is never seen in posttransplant anti-GBM nephritis in cases of Alport syndrome. Plasmapheresis and cyclophosphamide are generally unsuccessful, and most patients lose the allograft. [25] However, there have been cases of successful treatment with intravenous immunoglobulins and plasmapheresis."}
{"id": "article-17403_18", "title": "Alport Syndrome -- Histopathology", "content": "Initially, kidney biopsy specimens examined through light microscopy may be normal. As the disease progresses, non-specific findings may appear. These include focal and segmental glomerulosclerosis, tubular atrophy, interstitial fibrosis, and the presence of lymphocytes and plasma cells. Immunofluorescence studies yield negative results. Electron microscopy of the kidney reveals longitudinal splitting and multi-lamellation of the GBM lamina densa. [26] Monoclonal antibodies against alpha-3, alpha-4, and alpha-5 chains of type IV collagen may be used to assess the glomerular basement membrane for the presence or absence of these collagen chains. Their absence is strongly suggestive of Alport syndrome and is not seen in any other condition.", "contents": "Alport Syndrome -- Histopathology. Initially, kidney biopsy specimens examined through light microscopy may be normal. As the disease progresses, non-specific findings may appear. These include focal and segmental glomerulosclerosis, tubular atrophy, interstitial fibrosis, and the presence of lymphocytes and plasma cells. Immunofluorescence studies yield negative results. Electron microscopy of the kidney reveals longitudinal splitting and multi-lamellation of the GBM lamina densa. [26] Monoclonal antibodies against alpha-3, alpha-4, and alpha-5 chains of type IV collagen may be used to assess the glomerular basement membrane for the presence or absence of these collagen chains. Their absence is strongly suggestive of Alport syndrome and is not seen in any other condition."}
{"id": "article-17403_19", "title": "Alport Syndrome -- Histopathology", "content": "As the alpha-5 chain of type 4 collagen is also expressed in the epidermis, a skin biopsy can be used to establish a diagnosis. Immunofluorescence studies on skin biopsy specimens are often diagnostic. Patients with XLAS may also display abnormalities of alpha-2 collagen expression in the skin. [27] [28]", "contents": "Alport Syndrome -- Histopathology. As the alpha-5 chain of type 4 collagen is also expressed in the epidermis, a skin biopsy can be used to establish a diagnosis. Immunofluorescence studies on skin biopsy specimens are often diagnostic. Patients with XLAS may also display abnormalities of alpha-2 collagen expression in the skin. [27] [28]"}
{"id": "article-17403_20", "title": "Alport Syndrome -- History and Physical", "content": "A thorough history and physical examination must be obtained along with a family history. Laboratory evaluation\u00a0should include\u00a0urinalysis (UA), urine microscopy, and\u00a0renal function panel. Individuals with Alport syndrome may develop symptoms of hematuria, proteinuria, edema, hypertension, progressive decline in renal functions, and eventual ESRD. Over time, the symptoms worsen, and the patients experience worsening proteinuria, hypertension, a decline in GFR, and the development of ESRD. The time for the development of ESRD is around 16 to 35 years of age. They can also present with gross hematuria following an upper respiratory tract infection. [29]", "contents": "Alport Syndrome -- History and Physical. A thorough history and physical examination must be obtained along with a family history. Laboratory evaluation\u00a0should include\u00a0urinalysis (UA), urine microscopy, and\u00a0renal function panel. Individuals with Alport syndrome may develop symptoms of hematuria, proteinuria, edema, hypertension, progressive decline in renal functions, and eventual ESRD. Over time, the symptoms worsen, and the patients experience worsening proteinuria, hypertension, a decline in GFR, and the development of ESRD. The time for the development of ESRD is around 16 to 35 years of age. They can also present with gross hematuria following an upper respiratory tract infection. [29]"}
{"id": "article-17403_21", "title": "Alport Syndrome -- History and Physical", "content": "During late childhood, people with Alport syndrome frequently develop bilateral sensorineural hearing loss caused by abnormalities of type 4 collagen in the inner ear. [30] Hearing loss becomes apparent in late childhood or early adolescence, usually before the onset of kidney failure, and starts with high-frequency loss.", "contents": "Alport Syndrome -- History and Physical. During late childhood, people with Alport syndrome frequently develop bilateral sensorineural hearing loss caused by abnormalities of type 4 collagen in the inner ear. [30] Hearing loss becomes apparent in late childhood or early adolescence, usually before the onset of kidney failure, and starts with high-frequency loss."}
{"id": "article-17403_22", "title": "Alport Syndrome -- History and Physical", "content": "Multiple ocular findings can be seen\u00a0in patients with Alport syndrome. Affected individuals may have a cone-shaped lens (anterior lenticonus),\u00a0leading to abnormal refraction and decreased visual acuity.\u00a0Other abnormalities include\u00a0subcapsular cataracts, abnormal pigmentary changes in the retina with yellow or white flecks (dot-and-fleck retinopathy),\u00a0posterior polymorphous dystrophy, and corneal erosions. [31] [32] [33] [34] The following are the features in the history and examination, system-wise:", "contents": "Alport Syndrome -- History and Physical. Multiple ocular findings can be seen\u00a0in patients with Alport syndrome. Affected individuals may have a cone-shaped lens (anterior lenticonus),\u00a0leading to abnormal refraction and decreased visual acuity.\u00a0Other abnormalities include\u00a0subcapsular cataracts, abnormal pigmentary changes in the retina with yellow or white flecks (dot-and-fleck retinopathy),\u00a0posterior polymorphous dystrophy, and corneal erosions. [31] [32] [33] [34] The following are the features in the history and examination, system-wise:"}
{"id": "article-17403_23", "title": "Alport Syndrome -- History and Physical -- Renal", "content": "Gross or microscopic hematuria is the commonest and earliest sign of Alport syndrome. [35] It is more commonly seen in males. Like immunoglobulin, A nephropathy, around 60-70% of patients have episodes of gross hematuria, commonly precipitated by upper respiratory infection, in the first two decades of life. Hematuria is typically discovered in the first years of life in male patients. If there is no hematuria in a male patient in the first decade of life, he is less likely to have Alport syndrome. Proteinuria is generally absent in childhood but ultimately develops in males with XLAS and male and female patients with ARAS. [36] Incidence and severity increase with age and the extent of kidney failure. Hypertension develops by the second decade of life. Edema and nephrotic syndrome are observed in 30\u00a0to 40% of young patients with Alport syndrome; however, they are uncommon in early childhood. With the onset of kidney insufficiency, chronic anemia and osteodystrophy may manifest.", "contents": "Alport Syndrome -- History and Physical -- Renal. Gross or microscopic hematuria is the commonest and earliest sign of Alport syndrome. [35] It is more commonly seen in males. Like immunoglobulin, A nephropathy, around 60-70% of patients have episodes of gross hematuria, commonly precipitated by upper respiratory infection, in the first two decades of life. Hematuria is typically discovered in the first years of life in male patients. If there is no hematuria in a male patient in the first decade of life, he is less likely to have Alport syndrome. Proteinuria is generally absent in childhood but ultimately develops in males with XLAS and male and female patients with ARAS. [36] Incidence and severity increase with age and the extent of kidney failure. Hypertension develops by the second decade of life. Edema and nephrotic syndrome are observed in 30\u00a0to 40% of young patients with Alport syndrome; however, they are uncommon in early childhood. With the onset of kidney insufficiency, chronic anemia and osteodystrophy may manifest."}
{"id": "article-17403_24", "title": "Alport Syndrome -- History and Physical -- Hearing", "content": "Sensorineural\u00a0hearing loss is a characteristic feature observed commonly, but not universally, in Alport syndrome. Hearing loss is never congenital. Bilateral, high-frequency sensorineural deafness usually begins in late childhood or early adolescence, before the onset of kidney failure. Audiometry is an important tool to diagnose hearing loss at the beginning of the disease. As hearing loss progresses, patients require hearing aids. Hearing loss is always associated with renal involvement. Approximately 50% of male patients with XLAS have sensorineural\u00a0hearing impairment by the age of 25 years, and around 90% are deaf by 40 years.", "contents": "Alport Syndrome -- History and Physical -- Hearing. Sensorineural\u00a0hearing loss is a characteristic feature observed commonly, but not universally, in Alport syndrome. Hearing loss is never congenital. Bilateral, high-frequency sensorineural deafness usually begins in late childhood or early adolescence, before the onset of kidney failure. Audiometry is an important tool to diagnose hearing loss at the beginning of the disease. As hearing loss progresses, patients require hearing aids. Hearing loss is always associated with renal involvement. Approximately 50% of male patients with XLAS have sensorineural\u00a0hearing impairment by the age of 25 years, and around 90% are deaf by 40 years."}
{"id": "article-17403_25", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Anterior lenticonus, occurring in around 25% of patients with XLAS, is a characteristic feature of Alport syndrome. In this condition, the lens conically protrudes into the anterior chamber due to a thin basement membrane of the lens capsule.", "contents": "Alport Syndrome -- History and Physical -- Ocular. Anterior lenticonus, occurring in around 25% of patients with XLAS, is a characteristic feature of Alport syndrome. In this condition, the lens conically protrudes into the anterior chamber due to a thin basement membrane of the lens capsule."}
{"id": "article-17403_26", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Anterior lenticonus is generally not present at birth and is manifested by a slow worsening of vision, needing patients to change the prescription of their glasses frequently.", "contents": "Alport Syndrome -- History and Physical -- Ocular. Anterior lenticonus is generally not present at birth and is manifested by a slow worsening of vision, needing patients to change the prescription of their glasses frequently."}
{"id": "article-17403_27", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Anterior lenticonus is diagnosed by slit lamp examination.", "contents": "Alport Syndrome -- History and Physical -- Ocular. Anterior lenticonus is diagnosed by slit lamp examination."}
{"id": "article-17403_28", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Ultrastructure\u00a0assessment of the anterior lens capsule with the help of electron microscopy confirms Alport syndrome. [37]", "contents": "Alport Syndrome -- History and Physical -- Ocular. Ultrastructure\u00a0assessment of the anterior lens capsule with the help of electron microscopy confirms Alport syndrome. [37]"}
{"id": "article-17403_29", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Dot-and-fleck retinopathy\u00a0is the commonest ocular manifestation of Alport syndrome, occurring in around 85% of males with XLAS. Rarely seen in childhood, it typically appears at the onset of kidney failure. It is usually asymptomatic.\u00a0Numerous white and yellow dots and flecks occur around the macula in this condition. There is foveal sparing, but peripheries can get involved. Typically, dot-and-fleck retinopathy will not fluoresce with angiography.", "contents": "Alport Syndrome -- History and Physical -- Ocular. Dot-and-fleck retinopathy\u00a0is the commonest ocular manifestation of Alport syndrome, occurring in around 85% of males with XLAS. Rarely seen in childhood, it typically appears at the onset of kidney failure. It is usually asymptomatic.\u00a0Numerous white and yellow dots and flecks occur around the macula in this condition. There is foveal sparing, but peripheries can get involved. Typically, dot-and-fleck retinopathy will not fluoresce with angiography."}
{"id": "article-17403_30", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Posterior polymorphous corneal dystrophy\u00a0is rare in Alport\u00a0syndrome. Mostly, patients are asymptomatic, but some may develop gradually progressive visual impairment.\u00a0A rare\u00a0feature of Alport syndrome, it manifests as clear vesicles on the endothelial surface of the cornea. It is generally bilateral but can be unilateral.", "contents": "Alport Syndrome -- History and Physical -- Ocular. Posterior polymorphous corneal dystrophy\u00a0is rare in Alport\u00a0syndrome. Mostly, patients are asymptomatic, but some may develop gradually progressive visual impairment.\u00a0A rare\u00a0feature of Alport syndrome, it manifests as clear vesicles on the endothelial surface of the cornea. It is generally bilateral but can be unilateral."}
{"id": "article-17403_31", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "The mutation in the\u00a0COL4A5\u00a0gene rarely causes severe temporal macular thinning, a feature associated with XLAS. [38]", "contents": "Alport Syndrome -- History and Physical -- Ocular. The mutation in the\u00a0COL4A5\u00a0gene rarely causes severe temporal macular thinning, a feature associated with XLAS. [38]"}
{"id": "article-17403_32", "title": "Alport Syndrome -- History and Physical -- Ocular", "content": "Giant macular holes have been\u00a0reported in Alport syndrome case reports. The very large dimensions of macular holes were suggestive of a bad prognosis regarding the closure of the hole. [39]", "contents": "Alport Syndrome -- History and Physical -- Ocular. Giant macular holes have been\u00a0reported in Alport syndrome case reports. The very large dimensions of macular holes were suggestive of a bad prognosis regarding the closure of the hole. [39]"}
{"id": "article-17403_33", "title": "Alport Syndrome -- History and Physical -- Leiomyomatosis", "content": "Diffuse leiomyomatosis of the tracheobronchial tree and\u00a0esophagus has been observed in some families with Alport syndrome. [40] It generally becomes symptomatic in late childhood, and symptoms include dysphagia, postprandial vomiting, recurrent bronchitis, substernal or epigastric pain, dyspnea, stridor, and cough. Leiomyomatosis is confirmed on a computed tomography scan or magnetic resonance imaging.", "contents": "Alport Syndrome -- History and Physical -- Leiomyomatosis. Diffuse leiomyomatosis of the tracheobronchial tree and\u00a0esophagus has been observed in some families with Alport syndrome. [40] It generally becomes symptomatic in late childhood, and symptoms include dysphagia, postprandial vomiting, recurrent bronchitis, substernal or epigastric pain, dyspnea, stridor, and cough. Leiomyomatosis is confirmed on a computed tomography scan or magnetic resonance imaging."}
{"id": "article-17403_34", "title": "Alport Syndrome -- Evaluation", "content": "Patients typically present with persistent microscopic hematuria before the age of ten years. This is due to the defective glomerular basement membrane (GBM) permitting the passage of red blood cells. [41] The clinical suspicion for Alport syndrome should be high in patients with hematuria, proteinuria, abnormal renal indices, and ear and eye manifestations.\u00a0UA\u00a0would reveal blood and protein, and urine microscopy should be performed to evaluate for acanthocytes.", "contents": "Alport Syndrome -- Evaluation. Patients typically present with persistent microscopic hematuria before the age of ten years. This is due to the defective glomerular basement membrane (GBM) permitting the passage of red blood cells. [41] The clinical suspicion for Alport syndrome should be high in patients with hematuria, proteinuria, abnormal renal indices, and ear and eye manifestations.\u00a0UA\u00a0would reveal blood and protein, and urine microscopy should be performed to evaluate for acanthocytes."}
{"id": "article-17403_35", "title": "Alport Syndrome -- Evaluation", "content": "Renal biopsy is indicated in the setting of abnormal UA, presence of acanthocytes, red blood cell casts, or abnormal renal indices. Any patient with suspected Alport syndrome should be referred to otorhinolaryngology for the evaluation of high-frequency hearing loss and ophthalmology for the eye examination. Due to the defective collagen, the lens lacks the integrity to maintain the normal shape leading to the anterior lenticonus into the anterior chamber. [42] [43]", "contents": "Alport Syndrome -- Evaluation. Renal biopsy is indicated in the setting of abnormal UA, presence of acanthocytes, red blood cell casts, or abnormal renal indices. Any patient with suspected Alport syndrome should be referred to otorhinolaryngology for the evaluation of high-frequency hearing loss and ophthalmology for the eye examination. Due to the defective collagen, the lens lacks the integrity to maintain the normal shape leading to the anterior lenticonus into the anterior chamber. [42] [43]"}
{"id": "article-17403_36", "title": "Alport Syndrome -- Evaluation", "content": "Genetic testing can help establish the diagnosis and determine the inheritance pattern of an individual and their family members. Molecular genetic testing is non-invasive, accurate, and gives the prognosis as the underlying mutation can be revealed. Next-generation sequencing (NGS) analyses of COL4A3, COL4A4, and COL4A5 are recommended in patients with no family history of Alport syndrome. [15] [44] For patients with positive family history, testing the target gene is recommended. A renal biopsy is preferred if the genetic defect does not match the family genetic mutation. In males with XLAS, the GBM splitting increases from approximately 30% to more than 90% by the age of 30 years. [45]", "contents": "Alport Syndrome -- Evaluation. Genetic testing can help establish the diagnosis and determine the inheritance pattern of an individual and their family members. Molecular genetic testing is non-invasive, accurate, and gives the prognosis as the underlying mutation can be revealed. Next-generation sequencing (NGS) analyses of COL4A3, COL4A4, and COL4A5 are recommended in patients with no family history of Alport syndrome. [15] [44] For patients with positive family history, testing the target gene is recommended. A renal biopsy is preferred if the genetic defect does not match the family genetic mutation. In males with XLAS, the GBM splitting increases from approximately 30% to more than 90% by the age of 30 years. [45]"}
{"id": "article-17403_37", "title": "Alport Syndrome -- Evaluation", "content": "Patients without the characteristic GBM splitting can be identified by\u00a0immunostaining\u00a0the type 4 collagen of the alpha-3, alpha-4, and alpha-5 chains of the GBM. A less invasive procedure, a skin biopsy can be performed on a child with suspected\u00a0XLAS\u00a0using a monoclonal antibody against the alpha-5 of the type 4 collagen chain.", "contents": "Alport Syndrome -- Evaluation. Patients without the characteristic GBM splitting can be identified by\u00a0immunostaining\u00a0the type 4 collagen of the alpha-3, alpha-4, and alpha-5 chains of the GBM. A less invasive procedure, a skin biopsy can be performed on a child with suspected\u00a0XLAS\u00a0using a monoclonal antibody against the alpha-5 of the type 4 collagen chain."}
{"id": "article-17403_38", "title": "Alport Syndrome -- Treatment / Management", "content": "Unfortunately, there is no specific treatment for Alport syndrome. Treatment is focused on limiting the progression of proteinuria and kidney disease. Options include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) for managing proteinuria, hypertension, and CKD. Depending upon the degree of proteinuria, diuretics can be used. Although the treatment may delay the onset of renal impairment, most people affected by Alport will ultimately require dialysis or a kidney transplant. [46] [47] [1]", "contents": "Alport Syndrome -- Treatment / Management. Unfortunately, there is no specific treatment for Alport syndrome. Treatment is focused on limiting the progression of proteinuria and kidney disease. Options include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) for managing proteinuria, hypertension, and CKD. Depending upon the degree of proteinuria, diuretics can be used. Although the treatment may delay the onset of renal impairment, most people affected by Alport will ultimately require dialysis or a kidney transplant. [46] [47] [1]"}
{"id": "article-17403_39", "title": "Alport Syndrome -- Treatment / Management", "content": "ARB delays the progression of CKD or ESRD by reducing intra-glomerular pressure and proteinuria. Despite normal renal functions, initiating therapy with ARBs has been shown to have a significant impact on the development of ESRD. [48]", "contents": "Alport Syndrome -- Treatment / Management. ARB delays the progression of CKD or ESRD by reducing intra-glomerular pressure and proteinuria. Despite normal renal functions, initiating therapy with ARBs has been shown to have a significant impact on the development of ESRD. [48]"}
{"id": "article-17403_40", "title": "Alport Syndrome -- Treatment / Management", "content": "A small study found that combination therapy with an ARB, an ACE inhibitor, a statin, and a non-dihydropyridine calcium channel blocker safely ameliorated hypertension, albuminuria, lipid abnormalities, and glomerular selectivity in patients with Alport syndrome and halted progression in those without renal insufficiency. [49] A multicenter, placebo-controlled, randomized, double-blind trial of ramipril in children having Alport syndrome observed a decrease in the risk of disease progression by nearly half. [50]", "contents": "Alport Syndrome -- Treatment / Management. A small study found that combination therapy with an ARB, an ACE inhibitor, a statin, and a non-dihydropyridine calcium channel blocker safely ameliorated hypertension, albuminuria, lipid abnormalities, and glomerular selectivity in patients with Alport syndrome and halted progression in those without renal insufficiency. [49] A multicenter, placebo-controlled, randomized, double-blind trial of ramipril in children having Alport syndrome observed a decrease in the risk of disease progression by nearly half. [50]"}
{"id": "article-17403_41", "title": "Alport Syndrome -- Treatment / Management", "content": "The use of cyclosporine has not shown any benefit and is not recommended. For patients with ocular involvement, specifically anterior lenticonus, clear lens phacoemulsification with intraocular lens implantation can be considered. For patients with concomitant hearing loss, hearing aids are usually very effective. Hearing loss is not impacted by kidney transplantation. As with any hereditary disease, psychosocial support for all affected family members is essential. [51]", "contents": "Alport Syndrome -- Treatment / Management. The use of cyclosporine has not shown any benefit and is not recommended. For patients with ocular involvement, specifically anterior lenticonus, clear lens phacoemulsification with intraocular lens implantation can be considered. For patients with concomitant hearing loss, hearing aids are usually very effective. Hearing loss is not impacted by kidney transplantation. As with any hereditary disease, psychosocial support for all affected family members is essential. [51]"}
{"id": "article-17403_42", "title": "Alport Syndrome -- Treatment / Management", "content": "Patients with Alport syndrome have no contraindication for renal transplantation. There is no recurrence of the primary disease, as the transplanted kidney would have normal GBM.\u00a0Antibodies against\u00a0COL4A5 are found in males with\u00a0XLAS,\u00a0but very few patients also have antibodies against COL4A3. [52] [53] [54] [55]", "contents": "Alport Syndrome -- Treatment / Management. Patients with Alport syndrome have no contraindication for renal transplantation. There is no recurrence of the primary disease, as the transplanted kidney would have normal GBM.\u00a0Antibodies against\u00a0COL4A5 are found in males with\u00a0XLAS,\u00a0but very few patients also have antibodies against COL4A3. [52] [53] [54] [55]"}
{"id": "article-17403_43", "title": "Alport Syndrome -- Treatment / Management", "content": "Post renal transplantation, there is a 3% risk of de novo anti-GBM antibody disease or Alport posttransplant nephritis in XLAS with COL4A3. Generally, it relapses in the first year of transplantation. [32] [56] [57]", "contents": "Alport Syndrome -- Treatment / Management. Post renal transplantation, there is a 3% risk of de novo anti-GBM antibody disease or Alport posttransplant nephritis in XLAS with COL4A3. Generally, it relapses in the first year of transplantation. [32] [56] [57]"}
{"id": "article-17403_44", "title": "Alport Syndrome -- Treatment / Management", "content": "The affected patients typically possess circulating anti-GBM antibodies leading to crescentic glomerulonephritis and graft loss. [58] [59] Patients with ADAS do not appear to be at increased risk for de novo anti-GBM disease\u00a0following kidney transplantation. The treatment of post-transplant anti-GBM disease involves plasmapheresis along with cyclophosphamide and methylprednisolone with minimal benefit. Retransplantation in these patients has\u00a0a high risk of recurrence.", "contents": "Alport Syndrome -- Treatment / Management. The affected patients typically possess circulating anti-GBM antibodies leading to crescentic glomerulonephritis and graft loss. [58] [59] Patients with ADAS do not appear to be at increased risk for de novo anti-GBM disease\u00a0following kidney transplantation. The treatment of post-transplant anti-GBM disease involves plasmapheresis along with cyclophosphamide and methylprednisolone with minimal benefit. Retransplantation in these patients has\u00a0a high risk of recurrence."}
{"id": "article-17403_45", "title": "Alport Syndrome -- Differential Diagnosis", "content": "The differential diagnoses of Alport syndrome include the following: Immunoglobulin A nephropathy Thin GBM disease Acute post-streptococcal glomerulonephritis Medullary cystic disease Multicystic renal dysplasia Polycystic kidney disease", "contents": "Alport Syndrome -- Differential Diagnosis. The differential diagnoses of Alport syndrome include the following: Immunoglobulin A nephropathy Thin GBM disease Acute post-streptococcal glomerulonephritis Medullary cystic disease Multicystic renal dysplasia Polycystic kidney disease"}
{"id": "article-17403_46", "title": "Alport Syndrome -- Differential Diagnosis", "content": "The most important diagnostic consideration in patients with Alport syndrome is thin basement membrane (TBM) disease, a collagen 4-related nephropathy closely related to Alport syndrome. The same genes appear to be involved in many individuals with the disorder. Unlike those with Alport syndrome, few extra-renal findings are present, symptoms are less severe, with progression to renal impairment is rarely found. Differentiating these disease processes is challenging, particularly in younger or female patients who are less likely to have other associated symptoms. [60]", "contents": "Alport Syndrome -- Differential Diagnosis. The most important diagnostic consideration in patients with Alport syndrome is thin basement membrane (TBM) disease, a collagen 4-related nephropathy closely related to Alport syndrome. The same genes appear to be involved in many individuals with the disorder. Unlike those with Alport syndrome, few extra-renal findings are present, symptoms are less severe, with progression to renal impairment is rarely found. Differentiating these disease processes is challenging, particularly in younger or female patients who are less likely to have other associated symptoms. [60]"}
{"id": "article-17403_47", "title": "Alport Syndrome -- Prognosis", "content": "In the X-linked disease form, the most common type of Alport syndrome, about 50% of males require dialysis or kidney transplantation by 30 years, and approximately 90% develop ESRD before 40. [61] Female patients with X-linked Alport syndrome have a better prognosis, with about 12% developing end-stage renal disease (ESRD) by age 40. However, studies\u00a0indicate significant renal morbidity in females with proteinuria and hearing impairment. [62] [63]", "contents": "Alport Syndrome -- Prognosis. In the X-linked disease form, the most common type of Alport syndrome, about 50% of males require dialysis or kidney transplantation by 30 years, and approximately 90% develop ESRD before 40. [61] Female patients with X-linked Alport syndrome have a better prognosis, with about 12% developing end-stage renal disease (ESRD) by age 40. However, studies\u00a0indicate significant renal morbidity in females with proteinuria and hearing impairment. [62] [63]"}
{"id": "article-17403_48", "title": "Alport Syndrome -- Prognosis", "content": "By age 60, this rate increases to about 30%, and by 60 years of age, the rate of ESRD approaches 40%. In the female population, proteinuria and hearing loss are risk factors for the progression to ESRD. In comparison, the autosomal recessive form of Alport syndrome can cause kidney failure by age 20. In contrast, the autosomal dominant form of the disease typically has a delay in ESRD until middle age. [64]", "contents": "Alport Syndrome -- Prognosis. By age 60, this rate increases to about 30%, and by 60 years of age, the rate of ESRD approaches 40%. In the female population, proteinuria and hearing loss are risk factors for the progression to ESRD. In comparison, the autosomal recessive form of Alport syndrome can cause kidney failure by age 20. In contrast, the autosomal dominant form of the disease typically has a delay in ESRD until middle age. [64]"}
{"id": "article-17403_49", "title": "Alport Syndrome -- Complications", "content": "Alport syndrome affects multiple organ systems. It can lead to the following complications: End-stage renal disease (ESRD) Hearing loss Visual defects Leiomyomatosis (smooth muscle overgrowth in the respiratory and gastrointestinal tract) Aneurysms of the thoracic and abdominal aorta Mental retardation", "contents": "Alport Syndrome -- Complications. Alport syndrome affects multiple organ systems. It can lead to the following complications: End-stage renal disease (ESRD) Hearing loss Visual defects Leiomyomatosis (smooth muscle overgrowth in the respiratory and gastrointestinal tract) Aneurysms of the thoracic and abdominal aorta Mental retardation"}
{"id": "article-17403_50", "title": "Alport Syndrome -- Consultations", "content": "Alport syndrome is managed through a multidisciplinary approach as multiple organ systems are involved. An internist, intensivist, nephrologist, otorhinolaryngologist, ophthalmologist, and geneticist are involved in treating and managing Alport syndrome. Consultations with the following may also be necessary: Transplant surgeon Surgeon Dialysis specialist Audiologist", "contents": "Alport Syndrome -- Consultations. Alport syndrome is managed through a multidisciplinary approach as multiple organ systems are involved. An internist, intensivist, nephrologist, otorhinolaryngologist, ophthalmologist, and geneticist are involved in treating and managing Alport syndrome. Consultations with the following may also be necessary: Transplant surgeon Surgeon Dialysis specialist Audiologist"}
{"id": "article-17403_51", "title": "Alport Syndrome -- Deterrence and Patient Education", "content": "Patients should be given information leaflets regarding symptoms of renal failure and its systemic effects. Parents of affected children should be knowledgeable about the signs and symptoms of the disease that warrant hospital admission. Family members of patients with Alport syndrome should consult their primary care providers to go through screening as per the local guidelines. Patients with Alport syndrome should undergo genetic counseling before getting married and having children. There are various support groups available that can help patients and their families have better handling of their circumstances.", "contents": "Alport Syndrome -- Deterrence and Patient Education. Patients should be given information leaflets regarding symptoms of renal failure and its systemic effects. Parents of affected children should be knowledgeable about the signs and symptoms of the disease that warrant hospital admission. Family members of patients with Alport syndrome should consult their primary care providers to go through screening as per the local guidelines. Patients with Alport syndrome should undergo genetic counseling before getting married and having children. There are various support groups available that can help patients and their families have better handling of their circumstances."}
{"id": "article-17403_52", "title": "Alport Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Alport syndrome is a genetic disorder that affects multiple organs. The condition is best managed by an interprofessional team that includes a geneticist, nephrologist, ophthalmologist, otolaryngologist, and internist/pediatrician. Nurses and pharmacists are also part of this interprofessional team, counseling patients and working with their medications. In most cases, the disorder presents\u00a0during the first decade of life. Once the diagnosis is made, the workup of siblings and other family members is\u00a0recommended. Within the first three decades of life, most Alport syndrome patients develop ESRD and need dialysis. Here again, nurses and pharmacists will play a prominent role, the former in administering dialysis and the latter in fine-tuning drug dosing regimens around dialysis. All care team members must exercise open communication with the rest of the team and maintain accurate, updated records to ensure open information sharing among all professionals on the case.", "contents": "Alport Syndrome -- Enhancing Healthcare Team Outcomes. Alport syndrome is a genetic disorder that affects multiple organs. The condition is best managed by an interprofessional team that includes a geneticist, nephrologist, ophthalmologist, otolaryngologist, and internist/pediatrician. Nurses and pharmacists are also part of this interprofessional team, counseling patients and working with their medications. In most cases, the disorder presents\u00a0during the first decade of life. Once the diagnosis is made, the workup of siblings and other family members is\u00a0recommended. Within the first three decades of life, most Alport syndrome patients develop ESRD and need dialysis. Here again, nurses and pharmacists will play a prominent role, the former in administering dialysis and the latter in fine-tuning drug dosing regimens around dialysis. All care team members must exercise open communication with the rest of the team and maintain accurate, updated records to ensure open information sharing among all professionals on the case."}
{"id": "article-17403_53", "title": "Alport Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Collaboration and communication among the interprofessional team to enhance care coordination for patients\u00a0suffering from Alport syndrome is crucial to optimal patient outcomes. [Level 5]", "contents": "Alport Syndrome -- Enhancing Healthcare Team Outcomes. Collaboration and communication among the interprofessional team to enhance care coordination for patients\u00a0suffering from Alport syndrome is crucial to optimal patient outcomes. [Level 5]"}
{"id": "article-17403_54", "title": "Alport Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Alport Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}